Place of diclofenac in therapeutic standards in rheumatology Review article
Article Sidebar
Published:
Sep 30, 2021
Keywords:
diclofenac, pain, efficacy, safety
Main Article Content
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are drugs that are difficult to replace in the treatment of inflammatory pain. Both the mechanisms involved in the development of inflammatory pain and the individual characteristics of each non-steroidal anti-inflammatory drugs currently allow for personalized drug selection in such a way as to escalate its effectiveness while minimizing the risk of side effects. Diclofenac is a non-steroidal anti-inflammatory drug with one of the longest clinical experience. Since the beginning of the 70s of the last century, it has become an important element of everyday rheumatological practice, used in both degenerative and autoimmune diseases.
Article Details
How to Cite
Rupiński , R., & Woroń , J. (2021). Place of diclofenac in therapeutic standards in rheumatology. Medycyna Faktow (J EBM), 14(3(52), 274-278. https://doi.org/10.24292/01.MF.0321.9
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Schwinghammer TL, DiPiro JT, Ellingrod VL et al. Pharmacotherapy Handbook, McGraw Hill 2021.
2. Wiela-Hojeńska A, Jazwińska-Tarnawska E (ed). Niepożądane działania leków. MedPharm Polska, Wrocław 2019.
3. Tymiński R, Woroń J (ed). Niekorzystne interakcje leków. Aspekty kliniczne i prawne. Medical Tribune Polska, Warszawa 2020.
4. Shear NH. Drug Eruption & Reaction Manual. CRC Press, Boca Raton 2021.
5. Ray SD (ed). Side Effects of Drugs. Elsevier, Amsterdam 2019.
6. Dürrigl T, Vitaus M, Pucar I et al. Diclofenac sodium (Voltaren): results of a multi-centre comparative trial in adult-onset rheumatoid arthritis. J Int Med Res. 1975; 3(3): 139-44.
7. van Walsem A, Pandhi S, Nixon RM et al. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther. 2015; 17(1): 66. http://doi.org/10.1186/s13075-015-0554-0.
8. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368(9549): 1771-81.
9. Li M, Yu C, Zeng X. Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis. BMJ Open. 2020; 10(9): e036748. http://doi.org/10.1136/bmjopen-2019-036748.
10. Walker C, Essex MN, Li C et al. Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. J Int Med Res. 2016; 44(3): 483-95.
11. Diklofenak. Opis substancji (access: 2.07.2021).
12. Häuser W, Ablin J, Perrot S et al. Management of fibromyalgia: practical guides from recent evidence-based guidelines. Pol Arch Intern Med. 2017; 127(1): 47-56.
13. Smolen JS, Landewé RBM, Bijlsma JWJ et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79: 685-99.
14. Gossec L, Baraliakos X, Kerschbaumer A et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020; 79(6): 700-12.
15. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005; 64(suppl 2): ii74-ii7.
16. Fan M, Liu J, Zhao B et al. Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blinded, controlled trials. Exp Ther Med. 2020; 19(4): 3031-41.
17. Bruy O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019. http://doi.org/10.1016/j.semarthrit. 2019.04.008.
18.Kolasinski SL, Neogi T, Hochberg MC et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheum 2020; 0(0): 1-14. http://doi.org/10.1002/art.41142.
19. Tieppo Francio V, Davani S, Towery C et al. Oral versus topical diclofenac sodium in the treatment of osteoarthritis. J Pain Palliat Care Pharmacother. 2017; 31(2): 113-20.
20. Pavelka K. A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. Curr Med Res Opin. 2012; 28(1): 163-78.
2. Wiela-Hojeńska A, Jazwińska-Tarnawska E (ed). Niepożądane działania leków. MedPharm Polska, Wrocław 2019.
3. Tymiński R, Woroń J (ed). Niekorzystne interakcje leków. Aspekty kliniczne i prawne. Medical Tribune Polska, Warszawa 2020.
4. Shear NH. Drug Eruption & Reaction Manual. CRC Press, Boca Raton 2021.
5. Ray SD (ed). Side Effects of Drugs. Elsevier, Amsterdam 2019.
6. Dürrigl T, Vitaus M, Pucar I et al. Diclofenac sodium (Voltaren): results of a multi-centre comparative trial in adult-onset rheumatoid arthritis. J Int Med Res. 1975; 3(3): 139-44.
7. van Walsem A, Pandhi S, Nixon RM et al. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther. 2015; 17(1): 66. http://doi.org/10.1186/s13075-015-0554-0.
8. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368(9549): 1771-81.
9. Li M, Yu C, Zeng X. Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis. BMJ Open. 2020; 10(9): e036748. http://doi.org/10.1136/bmjopen-2019-036748.
10. Walker C, Essex MN, Li C et al. Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. J Int Med Res. 2016; 44(3): 483-95.
11. Diklofenak. Opis substancji (access: 2.07.2021).
12. Häuser W, Ablin J, Perrot S et al. Management of fibromyalgia: practical guides from recent evidence-based guidelines. Pol Arch Intern Med. 2017; 127(1): 47-56.
13. Smolen JS, Landewé RBM, Bijlsma JWJ et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79: 685-99.
14. Gossec L, Baraliakos X, Kerschbaumer A et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020; 79(6): 700-12.
15. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005; 64(suppl 2): ii74-ii7.
16. Fan M, Liu J, Zhao B et al. Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blinded, controlled trials. Exp Ther Med. 2020; 19(4): 3031-41.
17. Bruy O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019. http://doi.org/10.1016/j.semarthrit. 2019.04.008.
18.Kolasinski SL, Neogi T, Hochberg MC et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheum 2020; 0(0): 1-14. http://doi.org/10.1002/art.41142.
19. Tieppo Francio V, Davani S, Towery C et al. Oral versus topical diclofenac sodium in the treatment of osteoarthritis. J Pain Palliat Care Pharmacother. 2017; 31(2): 113-20.
20. Pavelka K. A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. Curr Med Res Opin. 2012; 28(1): 163-78.